Can I switch a patient from empagliflozin (Jardiance) 25 mg to dapagliflozin (Farxiga) and how should the transition be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, You Can Switch from Jardiance to Farxiga

You can safely switch your patient from empagliflozin (Jardiance) 25 mg to dapagliflozin (Farxiga) 10 mg, and the transition is straightforward—simply stop Jardiance and start Farxiga the next day without any washout period or dose titration. Both are SGLT2 inhibitors with proven cardiovascular and renal benefits, and they are considered therapeutically equivalent for most clinical purposes 1.

How to Make the Switch

Direct Substitution Protocol

  • Stop Jardiance 25 mg on the last day of use
  • Start Farxiga 10 mg the following day
  • No washout period needed
  • No dose titration required—start at full therapeutic dose of 10 mg daily 1

The standard therapeutic dose of dapagliflozin is 10 mg once daily, which provides comparable efficacy to empagliflozin 25 mg for cardiovascular and renal protection 1.

Important Clinical Considerations

Monitor These Parameters

  • eGFR: Check baseline kidney function before switching. Both drugs can be initiated down to eGFR ≥20 mL/min/1.73 m² 1
  • Volume status: Assess for signs of dehydration or hypotension, especially if patient is on diuretics
  • Blood glucose: If patient is on insulin or sulfonylureas, consider reducing doses to prevent hypoglycemia 1
  • Expect a temporary eGFR dip of 10-15% within the first 1-3 months—this is hemodynamic, not kidney injury, and should not prompt discontinuation 2, 3

Kidney Function Thresholds

Dapagliflozin has more flexible dosing at lower eGFR levels than empagliflozin:

  • Dapagliflozin: Can initiate down to eGFR ≥25 mL/min/1.73 m² (≥20 for heart failure indication) and continue until dialysis 1
  • Empagliflozin: Initiation not recommended with eGFR <30 mL/min/1.73 m² for glycemic control or <20 for heart failure 1

This actually makes dapagliflozin a better choice if your patient has declining kidney function, as it can be continued longer 1.

What to Tell Your Patient

Expected Effects

  • Glucose control: Equivalent glycemic efficacy between the two drugs 4, 5, 6
  • Cardiovascular protection: Both reduce heart failure hospitalization and cardiovascular death 1, 7
  • Kidney protection: Both slow CKD progression 8, 1, 9
  • Weight loss: Expect 2-3 kg reduction with either agent 10

Side Effects to Watch For

  • Genital mycotic infections: Occurs in ~6% of patients (more common in women and uncircumcised men) 1
  • Urinary tract infections: Monitor for symptoms
  • Volume depletion: Watch for dizziness, especially in first few weeks
  • Euglycemic DKA: Rare (0.1%) but serious—educate about sick day rules 1, 2

Sick Day Protocol (Critical)

Instruct patient to STOP Farxiga temporarily during:

  • Acute illness with vomiting/diarrhea
  • Dehydrating conditions
  • Before major surgery
  • Any condition causing reduced oral intake 1, 2

Resume once patient is eating/drinking normally and volume status is restored.

Medication Adjustments

If Patient is on Insulin or Sulfonylureas

Consider reducing doses by 10-20% when starting Farxiga to prevent hypoglycemia, especially if:

  • eGFR >45 mL/min/1.73 m² (where glucose-lowering effect is stronger)
  • HbA1c is already near target 1

If Patient is on Diuretics

Monitor volume status closely—the combination of SGLT2i with loop diuretics can cause additive diuresis 2. May need to reduce diuretic dose if patient develops orthostatic symptoms.

Evidence Quality Note

The 2022 ADA/KDIGO consensus guidelines 1 provide the strongest evidence base for this switch, establishing that SGLT2 inhibitors are a drug class with proven benefits and can be used interchangeably based on formulary considerations. Real-world studies 4, 6, 11 confirm that switching between these agents maintains efficacy and safety, though some data suggest empagliflozin may have slightly better adherence rates 11.

Common Pitfall to Avoid

Do not discontinue the SGLT2 inhibitor if eGFR drops 10-15% in the first 3 months—this is an expected hemodynamic effect that actually indicates the drug is working to protect the kidneys long-term 3, 2. Only stop if there's evidence of true acute tubular injury (check urine microscopy if concerned) or if eGFR drops >30% 2.

References

Guideline

kidney dysfunction in heart failure: core curriculum 2025.

American Journal of Kidney Diseases, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.